Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 14/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 4/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991290 | 0.84 | CYP1A2 (0.40) | PTK2CYP1A2CYP2C19SMN1; SMN2HTR3A | |
| SCHEMBL992615 | 0.82 | HTR3A (0.43) | PTK2CYP1A2HTR3ATACR1HRH4 | |
| SCHEMBL989945 | 0.81 | HTR3A (0.43) | CYP1A2CYP2C19HTR3A | |
| SCHEMBL990803 | 0.77 | MAPT (0.45) | CYP1A2CYP2C19SMN1; SMN2HTR3AHRH4 | |
| SCHEMBL856329 | 0.74 | PTK2 (0.47) | PTK2CYP1A2CYP2C19SMN1; SMN2HTR3A | |
| SCHEMBL989996 | 0.73 | CYP1A2 (0.37) | PTK2CYP1A2CYP2C19SMN1; SMN2HTR3A | |
| SCHEMBL991309 | 0.70 | WNT1 (0.49) | SMN1; SMN2HTR3AHRH4 | |
| SCHEMBL1996892 | 0.69 | HTR3A (0.62) | HTR3AHRH4 | |
| SCHEMBL22652074 | 0.69 | HTR3A (0.49) | HTR3AHRH4 | |
| SCHEMBL989988 | 0.68 | HTR3A (0.39) | CYP1A2HTR3ATACR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2270001-A1 | Indolylmaleimide derivatives as PKC inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| CN-101933926-A | Indolylmaleimde derivatives as PKC inhibitors | NOVARTIS AG | 2011-01-05 | — | — | CN | disclosed |
| CN-1910173-B | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG | 2010-06-09 | — | — | CN | disclosed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| CN-1910173-A | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | PTK2 1045/4885CYP1A2 4077/4885CYP2C19 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.